No headlines found.
PRNewswire (Wed, 28-Jan 7:00 AM ET)
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
Calcimedica trades on the NASDAQ stock market under the symbol CALC.
As of February 17, 2026, CALC stock price declined to $0.61 with 416,754 million shares trading.
CALC has a beta of 0.57, meaning it tends to be less sensitive to market movements. CALC has a correlation of 0.00 to the broad based SPY ETF.
CALC has a market cap of $8.82 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that CALC belongs to (by Net Assets): VTI, VXF.
CALC has underperformed the market in the last year with a price return of -77.1% while the SPY ETF gained +13.2%. CALC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -81.0% and -31.9%, respectively, while the SPY returned +1.9% and -1.3%, respectively.
CALC support price is $.59 and resistance is $.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CALC shares will trade within this expected range on the day.
